Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1817 results
May 2017
-
Media ReleaseAt the Meet Novartis Management investor event, Novartis highlights focus on innovation and productivity; expects the next growth phase to begin in 2018Building depth across key therapeutic areas with 12 potential blockbusters in late stage development and 40 potential filings in US and EU between 2017-2020 Focused and taking steps to become…
-
Media ReleaseNovartis next generation CAR-T cell therapy CTL119 combined with ibrutinib shows high rate of responses in CLL patientsEight of nine evaluable patients tested had no signs of CLL in their bone marrow at three months.CTL119 is a humanized CD19-directed CAR-T cell therapy being developed in collaboration with the…
-
Media ReleaseNovartis receives FDA approval for expanded use of Zykadia® in first-line ALK-positive metastatic non-small cell lung cancer (NSCLC)In ALK-positive metastatic NSCLC patients, Zykadia median progression-free survival (PFS) was 16.6 months, compared to 8.1 months with chemotherapy[1] The overall intracranial response rate…
-
Going global to meet local needs in China
Marc Pelletier traveled from Cambridge, MA to Shanghai, China, to launch new lines of research for the treatment of cancers that are common in China.
-
Choosing the right care
Melanoma survivor T.J. Sharpe shares why patients should know their treatment options.
-
Media ReleaseNovartis' new analyses reinforce the potential of Ultibro® Breezhaler® for COPD patients historically treated with steroidsNew analyses from the FLAME study suggest dual bronchodilator Ultibro® Breezhaler® provides similar or better efficacy versus steroid-containing therapies, regardless of blood eosinophil (a type of…
-
Media ReleaseNovartis receives positive CHMP opinion for first-line use of Zykadia® in ALK-positive advanced non-small cell lung cancer (NSCLC)Phase III trial, first-line treatment with Zykadia resulted in improved progression-free survival (PFS) over SOC chemotherapy with maintenance, including in patients with brain metastases[1]…
-
Media ReleaseNovartis data at ASCO, ICML and EHA meetings demonstrate meaningful advancements in cancer careUpdated analyses from the Kisqali® pivotal Phase III MONALEESA-2 trial in hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer to be…
-
Media ReleaseNovartis Foundation and partners launch initiative to tackle hypertension and its root causes in low-income urban communitiesBetter Hearts Better Cities is a Novartis Foundation initiative to improve cardiovascular health in low-income urban communities by addressing the prevention, management and control of hypertension…
-
Women in Science: Renee Rodgers
-
Novartis invites scrutiny of effort to improve access to medicine
Public health expert Richard Laing discusses how independent measurement of access programs can help ensure their success
-
In The NewsNovartis Access and government of Pakistan sign memorandum of understandingNovartis reaches agreement with Pakistan to increase access to medicines that address the rapid rise of chronic illness among poor people in the world's sixth most populous nation.
Pagination
- ‹ Previous page
- 1
- …
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- …
- 152
- › Next page